Indirubin-3′-monoxime

A potent cell-permeable, reversible, and ATP-compatible inhibitor of glycogen synthase kinase-3β (IC₅₀ = 22 nM) and cyclin-dependent kinases (IC₅₀ = 180 nM for Cdk1 and 100 nM for Cdk5). Inhibits the proliferation of a large range of cells by arresting them in the G₂/M phase of the cell cycle. Inhibits Tau phosphorylation in vitro and in vivo at Alzheimer′s disease-specific sites. Also reported to inhibit the in vivo phosphorylation of DARPP-32 by Cdk5 on Thr⁷⁵.

A potent, reversible, and ATP-compatible inhibitor of GSK-3β (glycogen synthase kinase 3β), Cdk1 (cyclin-dependent kinase1) and Cdk5 (IC₅₀ = 22 nM, 180 nM, and 100 nM, respectively). Inhibits the proliferation of a large range of cells by arresting them in the G₂/M phase of the cell cycle. Inhibits Tau phosphorylation in vitro and in vivo at Alzheimer’s disease-specific sites. Also reported to inhibit the in vivo phosphorylation of DARPP-32 by Cdk5 on Thr⁷⁵.

Cell permeable: yes

Primary Target
Gsk-3β

Product competes with ATP.

Reversible: yes

Target IC₅₀: 22 nM, 180 nM, and 100 nM against GSK-3β, Cdk1, and Cdk5, respectively

Packaged under inert gas

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Bain, J., et al. 2003. Biochem. J. 371, 199.
Leclerc, S., et al. 2000. J. Biol. Chem.276, 251.
Hoessel, R., et al. 1999. Nat. Cell Biol. 1, 60.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany